0RD1.L - Camurus AB (publ)

LSE - LSE Delayed price. Currency in SEK

Camurus AB (publ)

Ideon Science Park
Lund 223 70
46 4 62 86 57 30

Full-time employees117

Key executives

NameTitlePayExercisedYear born
Mr. Fredrik TibergPres, CEO & Director8.09MN/A1963
Ms. Eva Pinotti-LindqvistChief Financial OfficerN/AN/A1963
Mr. Torsten MalmströmVP of Technical OperationsN/AN/A1968
Mr. Rein Piir B.Sc.VP of Investor RelationsN/AN/A1958
Mr. Urban PaulssonVP of Corp. Devel. & Gen. CounselN/AN/A1963
Amounts are as of 31 December 2018, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.


Camurus AB (publ), a research-based pharmaceutical company, develops and commercializes pharmaceuticals for serious and chronic conditions in Sweden, North America, and internationally. The company's development pipeline contains product candidates for the treatment of cancer and the side effects of cancer treatment, endocrine diseases, pain, opioid dependence, and addiction. It also offers episil oral liquid, a medical device for the treatment of inflammatory and painful conditions. The company was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) is a subsidiary of Sandberg Development AB.

Corporate governance

Camurus AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more